The FDA has expanded the use of Pfizer’s Abrysvo RSV vaccine, now offering protection to adults aged 18-59 at high risk for respiratory illness. This move broadens the vaccine’s reach, providing a vital safeguard against RSV for a larger population, including pregnant women who can protect their infants. The decision is based on the success of the MONeT study, highlighting the vaccine’s safety and effectiveness. The approval comes as RSV vaccine sales have declined following regulatory adjustments, underscoring the crucial role Abrysvo plays in building new revenue streams for Pfizer.